<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               7 DRUG INTERACTIONS<BR>               <BR>                  <BR>                     Effects of other drugs<BR>                  <BR>                  Ticagrelor is predominantly metabolized by CYP3A4 and to a lesser extent by CYP3A5.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           <BR>                              •Avoid use with strong CYP3A inhibitors or CYP3A inducers. (7.1, 7.2) <BR>                           <BR>                              •Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. (7.3)<BR>                           <BR>                              •Monitor digoxin levels with initiation of or any change in BRILINTA. (7.4)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.1 CYP3A inhibitors<BR>                     <BR>                        Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.2 CYP3A inducers<BR>                     <BR>                        Avoid use with potent inducers of CYP3A (e.g., rifampin, dexamethasone, phenytoin, carbamazepine and phenobarbital) [see Warnings and Precautions (5.7) and Clinical Pharmacology (12.3)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.3 Aspirin<BR>                     <BR>                        Use of BRILINTA with aspirin maintenance doses above 100 mg reduced the effectiveness of BRILINTA [see Warnings and Precautions (5.2) and Clinical Studies (14)].<BR>                        <BR>                        <BR>                           Effect of BRILINTA on other drugs <BR>                        <BR>                        Ticagrelor is an inhibitor of CYP3A4/5 and the P-glycoprotein transporter.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.4 Simvastatin, lovastatin<BR>                     <BR>                        BRILINTA will result in higher serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg [see Clinical Pharmacology (12.3)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.5 Digoxin<BR>                     <BR>                        <BR>                           Digoxin: Because of inhibition of the P-glycoprotein transporter, monitor digoxin levels with initiation of or any change in BRILINTA therapy [see Clinical Pharmacology (12.3)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.6 Other Concomitant Therapy<BR>                     <BR>                        BRILINTA can be administered with unfractionated or low-molecular-weight heparin, GPIIb/IIIa inhibitors, proton pump inhibitors, beta-blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>